Study record
TA-65 and immune / telomere markers in a health-maintenance program (Harley et al., 2011)
Human non-randomized biomarker evaluation — commercial programme (no control group)
Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase expression is low in many differentiated normal tissues, while some normal proliferating cells can express it. Cancer can also use telomere maintenance; the included human records do not resolve long-term cancer risk from pharmacological activation. Tellingly, the FDA-approved telomerase inhibitor — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.
○ Evidence tier 4 — Human pilot / observational — biomarker
Record verify: source publication identified; see evidence and limitations
| Design | Non-randomized, uncontrolled biomarker evaluation within a commercial health-maintenance programme (PattonProtocol-1) |
| PMID | 20822369 |
| PMCID | PMC3045570 |
| DOI | 10.1089/rej.2010.1085 |
| Citation status | Original publication identity matched by title, author and DOI; relevant full-text sections, results and limitations examined 2026-10-14. |
Five-qualifier claim
| Species / population | Older adults enrolled in a commercial health-maintenance program (TA-65 evaluated with a range of biomarkers). |
| Exposure, route, schedule | Oral TA-65 10-50 mg daily, given as part of a bundle: the PattonProtocol-1 programme also included a comprehensive dietary supplement pack and physician counselling with periodic laboratory tests. |
| Comparator / duration | No control group and no randomization. Biomarker follow-up at 3, 6, 9 and 12 months within the programme. |
| Endpoint / numeric result | Declines in the percentage of senescent cytotoxic (CD8+/CD28-) T cells at 6, 9 and 12 months (p=0.018, 0.0024, 0.0062) and in natural killer cells at 6 and 12 months (p=0.028, 0.00013), mostly in cytomegalovirus-seropositive subjects. Mean telomere length did NOT increase; what changed was the percentage of short (<4 kbp) telomeres (p=0.037). |
| What it did NOT establish | Because TA-65 was given together with a supplement pack and physician counselling, no observed change can be attributed to TA-65 itself. With no control group there is no causal claim available at all. Mean telomere length did not increase, so this is not evidence of telomere lengthening in general. Commercial conflict of interest: lead author affiliated with the company developing the compound. No healthy-aging, clinical-outcome or lifespan benefit is established. |
Interventions
Primary reference
https://doi.org/10.1089/rej.2010.1085
Each identifier above was confirmed against the primary record; the citation status names the source and the date. An identifier that could not be confirmed is left empty and named as such in the record, never filled in from a secondary source.